便微生物群移植的成本效益与早期Clostridioides difficile感染的万科米辛单疗法相比:经济评估与随机对照试验一起进行
C R Birch1, S E Paaske2, M B Jensen3
1Nordic Institute of Health Economics, Aarhus, Denmark.
The Journal of hospital infection
|November 15, 2024
概括
便微生物种移植 (FMT) 是早期Clostridioides difficile感染 (CDI) 的成本有效的治疗方法,与标准护理相比,降低了医院费用和改善了结果.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 卫生经济学 卫生经济学
背景情况:
- 困难菌感染 (CDI) 通常需要多次治疗.
- 便微生物群移植 (FMT) 建议用于复发性CDI.
- 对于第一个或第二次CDI发作,正在探索使用FMT进行早期干预.
研究的目的:
- 评估FMT与早期CDI标准护理的医院费用.
- 为了比较FMT作为CDI早期治疗的经济影响.
主要方法:
- 随机对照试验 (RCT) 将FMT与标准护理进行比较.
- 在26周期间对医院费用的分析.
- 敏感性分析以确定成本效益值.
主要成果:
- 与标准护理相比,FMT在26周内降低了1,645欧元的医院费用.
- 减少住院,接触,和药物使用被观察到与FMT.
- FMT仍然具有成本效益,总治疗成本门为3,144.4欧元.
结论:
- FMT是早期CDI治疗的成本效益高的策略.
- FMT显示成本更低,效率更高,而不是单独使用万科米辛治疗.
- 在敏感性分析中,FMT的成本效益是稳定的.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
603
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
603
Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs for Treatment of Constipation-Predominant IBS
1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Automated Microbial Diagnostics
83
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
83


